Navigation Links
Varian Medical Systems to Showcase Fast, Precise Brachytherapy Planning System at Annual Meeting of American Association of Physicists in Medicine
Date:7/14/2010

PHILADELPHIA, July 14 /PRNewswire-FirstCall/ -- A significantly more accurate* way of calculating the dosimetry of cancer treatments will be spotlighted by Varian Medical Systems (NYSE: VAR) at the American Association of Physicists in Medicine (AAPM) annual meeting at the Pennsylvania Convention Center in Philadelphia from July 18th-22nd. Acuros® BV enables clinicians to rapidly calculate patient doses for brachytherapy radiotherapy treatments with an extremely high level of accuracy.

"This is a major step forward in terms of accuracy with timeframes that were previously thought unimaginable," says Sophie Wetherall, Varian BrachyTherapy software product manager. "Acuros BV offers an improvement in dose calculation that will help clinicians make better decisions about dose to their patients and further their knowledge and ability to make treatments even more accurate."

Since its introduction in 2009, clinicians have been researching the dosimetric calculation capabilities of Acuros BV and some leading brachytherapy practitioners and academics will be presenting papers at AAPM on the subject.

Research

Dr. Dorin Todor, M.D., head of brachytherapy at Virginia Commonwealth University in Richmond, Virginia, says, "While Monte Carlo software packages have existed for a long time, the tediousness of using them, combined with hours or days of running the algorithms, have made them virtually impractical for use in the clinic, rendering them useful to only a handful of researchers for mostly academic purposes. By comparison, Acuros appears to be a major step forward in accuracy and speed."

Professor Mark Rivard, PhD, professor of radiation oncology and chief medical physicist at Tufts Medical Center in Boston, says, "I have been evaluating the Acuros BV system since mid-2009 and it is clear the sophisticated dose calculation algorithm is revolutionary for brachytherapy, with speed that is phenomenal compared to Monte Carlo-based calculations." Prof. Rivard said he finds that Acuros BV will provide more accurate HDR (high dose rate) brachytherapy dose distributions than previously clinically possible.

Dr. Firas Mourtada, of MD Anderson in Houston, Texas, will be presenting his findings at AAPM following a retrospective comparison of TG-43 dose calculations and Acuros BV for breast patients.  

Dose calculations

Dose levels for brachytherapy have generally been calculated as if the sources are surrounded by water, whereas in reality a patient's anatomy contains many different materials such as bone, lung, tissue and air, as well as additional materials that are often present from inserted applicators. In the past the only way to account for this was using Monte Carlo calculation techniques, something that was only available as a research tool. Now, for the first time in routine clinical brachytherapy, Acuros BV is able to account for the dose effects from these variations.

"Acuros BV calculation times tend to average between three and eight minutes depending on the applicator used," adds Sophie Wetherall. "By comparison, the same calculations could take hours or days using the standard Monte Carlo method."

Professor Panos Papagiannis, and his team at the department of medical physics at the University of Athens in Greece carried out an independent dosimetric accuracy check of the new system. "We implemented a series of tests following a graded approach and concluded that Acuros BV is the first treatment planning system that not only handles standard TG-43 based calculations but also incorporates the capability to accurately calculate truly individualized patient dose distributions," said Prof. Papagiannis.

As well as Acuros BV, Varian Medical Systems will be exhibiting its full range of brachytherapy hardware and software solutions at AAPM.

*Compared to standard techniques using the American Association of Physicists in Medicine TG-43 formulism.

Editorial contact: Neil Madle, Varian Medical Systems, +44 7786 526068

About Varian Medical Systems

Varian Medical Systems, Inc., of Palo Alto, California, is the world's leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, proton therapy, and brachytherapy. The company supplies informatics software for managing comprehensive cancer clinics, radiotherapy centers and medical oncology practices. Varian is a premier supplier of tubes and digital detectors for X-ray imaging in medical, scientific, and industrial applications and also supplies X-ray imaging products for cargo screening and industrial inspection. Varian Medical Systems employs approximately 5,000 people who are located at manufacturing sites in North America, Europe, and China and approximately 79 sales and support offices around the world. For more information, visit http://www.varian.com.


'/>"/>
SOURCE Varian Medical Systems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Bavarian Nordic Delivers 1 Million Doses of First Vaccine Developed Under U.S. Biopreparedness Program to the Strategic National Stockpile
2. Al Amal Hospital in Qatar Commences Treatments Using Fast and Efficient RapidArc Radiotherapy Technology from Varian Medical Systems
3. Varian Medical Systems Equips International Oncologys First Comprehensive Cancer Center in India
4. Prostate Cancer Patient First in Spain to Receive Fast and Precise RapidArc(R) Radiotherapy Treatment from Varian
5. Varian Medical Systems Introduces ProBeam(TM) Proton Therapy Platform at Particle Therapy Co-operative Group (PT COG) 2010 Meeting
6. Varian Medical Systems Equips Three Leading Cancer Centers in Istanbul with Advanced Radiotherapy Technology
7. Leading Varian-Equipped Proton Therapy Center Treats 100th Patient
8. Varian Medical Systems Showcases Advanced Radiotherapy and Brachytherapy Products at ACRO 2010, February 25-27, Florida, Booth No. 34-35
9. Abbott Submits New Automated Ovarian Cancer Test for U.S. Approval
10. Hope International Centro de Radioterapia of Guatemala Becomes First in Latin America to Treat Cancer Using RapidArc(R) Radiotherapy Technology From Varian Medical Systems
11. Slovenias Sole Radiotherapy Hospital Unveils Novalis Tx(TM) Platform From Varian and BrainLAB
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... June 24, 2016  Arkis BioSciences, a leading ... and more durable cerebrospinal fluid treatments, today announced ... Series-A funding is led by Innova Memphis, followed ... other private investors.  Arkis, new financing will accelerate ... the market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... June 23, 2016 Research and ... Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), ... Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is projected ... CAGR of 6.1% in the forecast period 2016 to ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal their media ... Pro X," said Christina Austin - CEO of Pixel Film Studios. , ProSlice ... X users can now reveal the media of their split screens with growing ...
(Date:6/26/2016)... (PRWEB) , ... June 27, 2016 , ... Quality metrics ... yet in many ways they remain in the eye of the beholder, according to ... a publication of The American Journal of Managed Care. For the full issue, ...
(Date:6/26/2016)... , ... June 26, 2016 , ... ... once they have been diagnosed with endometriosis. These women need a treatment plan ... require a comprehensive approach that can help for preservation of fertility and ultimately ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... First ... United States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell ... facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published ... unfamiliar with. The article goes on to state that individuals are now more comfortable ... less common operations such as calf and cheek reduction. The Los Angeles area medical ...
Breaking Medicine News(10 mins):